Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib + abiraterone acetate fixed-dose combination bioavailability and bioequivalence study in men with metastatic castration-resistant prostate cancer
NL-OMON58706Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of niraparib and abiraterone in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Relative bioavailability of low-strength fixed-dose combination tablet and Bioequivalence of regular-strength fixed-dose combination tablet. Started Dec 2020; status: completed.
02
Drugs
niraparibabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON58706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58706.